Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brii Biosciences

https://www.briibio.com/

Latest From Brii Biosciences

China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light

Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.

China Coronavirus COVID-19

Coronavirus Update: Brii Files US EUA For Antibody Combo

Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral. 

Coronavirus COVID-19 Biologics

Coronavirus Update: J&J Highlights Positive Booster Shot Data

Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.

Coronavirus COVID-19 Vaccines

Antibody COVID-19 Therapies Back in China Spotlight Amid Infection Surge

Chinese developers forge ahead with research into antibody therapies for COVID-19 as coronavirus variants gain a toe-hold in the country.

China Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Brii Biosciences Limited
UsernamePublicRestriction

Register